

Impact of long-term quorum sensing inhibition on uropathogenic Escherichia coli.

HENLY, EL, NORRIS, K, RAWSON, K, ZOULIAS, N, JAQUES, L, CHIRILA, PG, PARKIN, KL, KADIRVEL, M, WHITEOAK, C, LACEY, Melissa <<http://orcid.org/0000-0003-0997-0217>>, SMITH, TJ and FORBES, Sarah <<http://orcid.org/0000-0002-8361-6390>>

Available from Sheffield Hallam University Research Archive (SHURA) at:

<http://shura.shu.ac.uk/28017/>

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it.

Published version

HENLY, EL, NORRIS, K, RAWSON, K, ZOULIAS, N, JAQUES, L, CHIRILA, PG, PARKIN, KL, KADIRVEL, M, WHITEOAK, C, LACEY, Melissa, SMITH, TJ and FORBES, Sarah (2021). Impact of long-term quorum sensing inhibition on uropathogenic Escherichia coli. *Journal of Antimicrobial Chemotherapy*.

Copyright and re-use policy

See <http://shura.shu.ac.uk/information.html>

Impact of long-term quorum sensing inhibition on uropathogenic *Escherichia coli*

1 **E.L. Henly¹, K. Norris¹, K. Rawson¹, N. Zoulias², L. Jaques¹, P.G. Chirila¹, K.L.**
2 **Parkin¹, M. Kadirvel³, C. Whiteoak¹, M.M. Lacey¹, T.J. Smith¹ & S. Forbes^{1*}**

3 ¹Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK

4 ²Department of Molecular Biology and Biotechnology, University of Sheffield, UK.

5 ³Manchester Pharmacy School, University of Manchester, UK.

6
7 Running title: Quorum sensing inhibitor activity in UPEC

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

24 *For Correspondence: Dr Sarah Forbes. Biomolecular Sciences Research Centre. College of
25 Health, Wellbeing and Life Sciences, Sheffield Hallam University, Sheffield, S1 1WB. Tel:
26 0114 225 3075. Email: S.Forbes@shu.ac.uk

27 **Synopsis**

28 **Background:** Quorum sensing is an extracellular bacterial communication system used in the
29 density-dependent regulation of gene expression and development of biofilms. Biofilm-
30 formation has been implicated in the establishment of catheter-associated urinary tract
31 infections (CAUTIs), therefore quorum sensing inhibitors (QSIs) have been suggested as anti-
32 biofilm catheter coating agents. The long-term effects of QSIs in uropathogens is however not
33 clearly understood. We evaluated the effects of repeated exposure to the QSIs cinnamaldehyde,
34 (Z)-4-Bromo-5(bromomethylene)-2(5H)-furanone (C30) and 4-fluoro-5-hydroxypentane-2,3-
35 dione (F-DPD) on antimicrobial susceptibility, biofilm-formation and relative pathogenicity in
36 eight uropathogenic *Escherichia coli* (UPEC) isolates. **Methods:** Minimum inhibitory,
37 bactericidal and biofilm eradication concentrations and antibiotic susceptibility were
38 determined. Biofilm-formation was quantified using crystal-violet. Relative-pathogenicity was
39 assessed in a *Galleria mellonella* model. To correlate changes in phenotype to gene expression,
40 transcriptomic profiles were created through RNA-sequencing and variant analysis of genomes
41 was performed in strain EC958. **Results:** Cinnamaldehyde and furanone-C30 led to increases
42 in susceptibility in planktonic and biofilm-associated UPEC. Relative-pathogenicity increased
43 after cinnamaldehyde exposure (4/8 isolates), decreased after furanone-C30 exposure (6/8
44 isolates) and varied after F-DPD exposure (one increased and one decreased). 9 out of 21 strains
45 with putative antibiotic cross-resistance were generated. Exposure to cinnamaldehyde or F-
46 DPD reduced expression of genes associated with locomotion, whilst cinnamaldehyde caused
47 an increase in genes encoding fimbrial and afimbrial like adhesins. Furanone C30 caused a
48 reduction in genes involved in cellular biosynthetic processes likely though impaired
49 ribonucleoprotein assembly. **Conclusion:** The multiple phenotypic adaptations induced during
50 QSI exposure in UPEC should be considered when selecting an anti-infective catheter coating
51 agent.

52 **Introduction**

53 Urinary tract infection (UTI) is the most common healthcare associated infection, with between
54 43% and 56% of cases associated with the presence of an indwelling urethral catheter.¹ The
55 treatment of catheter associated urinary tract infection (CAUTI) is complicated by the
56 emergence of uropathogenic *E. coli* (UPEC) exhibiting multiple antibiotic resistances.² In
57 Europe and the US 50,000 people a year lose their lives due to antibiotic-resistant pathogens,
58 with that number rising to 700,000 worldwide.³ This number is predicted to reach 10 million
59 deaths by 2050 if alternative therapies are not found.³ There has therefore been substantial
60 interest in the development of strategies to help prevent CAUTI that avoid the use of antibiotics.

61 Biocide-impregnated catheter coatings have shown promise in reducing the incidence of
62 CAUTI in clinical trials.⁴ However, concerns over the selection of biocide-resistant bacterial
63 populations, in addition to the induction of cross-resistance to third party agents such as
64 antibiotics, has led to the search for new strategies.⁵ An alternative approach is to use quorum
65 sensing inhibitors (QSIs) as anti-infective catheter coatings. Quorum sensing (QS) is a process
66 by which bacteria produce and detect extracellular signalling molecules and coordinate their
67 behaviour in a cell density dependent manner.⁶ QS has been shown to be an important
68 contributor to the formation of bacterial biofilms and expression of virulence factors in certain
69 bacterial species.⁷ QSIs disrupt such communicative processes and provide a potential strategy
70 to prevent the establishment of biofilm associated infections such as CAUTI, whilst exhibiting
71 limited cytotoxic effects since they are generally specific to their bacterial targets.

72 Quorum sensing in UPEC is mediated by autoinducer-2 (AI-2)-based signaling⁸ AI-2 consists
73 of derivatives of 4,5-dihydroxy-2,3-pentanedione (DPD)⁹ with the synthase enzyme LuxS
74 present in more than 500 bacterial species.⁸⁻⁹ AI-2 production is directly correlated to biofilm
75 production in *E.coli* through regulation of the motility quorum-sensing regulator gene *mqsR*

76 which encodes an mRNA interferase.¹⁰ DPD analogues have been shown to prevent AI-2
77 binding to the periplasmic receptor LsrB¹¹ disrupting AI-2 based transduction and have
78 exhibited anti-biofilm activity in *E. coli*.¹² We have demonstrated previously that 4-fluoro-5-
79 hydroxypentane-2,3-dione (F-DPD), a novel fluoro DPD analogue, disrupts AI-2-based QS.¹³
80 ¹⁴ A small number of diverse natural compounds have also been shown to inhibit AI-2-based
81 signalling. (Z)-4-Bromo-5(bromomethylene)-2(5H)-furanone-C30 (furanone-C30), produced
82 by the red alga *Delisea pulchra*, reduced AI-2 based QS in *E. coli* as well as decreasing
83 swarming motility and biofilm-formation.¹⁵ Cinnamaldehyde, which is obtained from the bark
84 of the cinnamon tree, has also been shown to interfere with AI-2 based signaling¹⁶ and is
85 believed to modulate virulence factor expression in UPEC decreasing urothelial cell attachment
86 and invasion.¹⁷

87 Exposure of bacteria to sub-lethal concentrations of antimicrobials, such as found when
88 compounds leach from a coated medical device surface forming a gradient, creates a selective
89 pressure which can select for intrinsically resistant mutants or induce phenotypic adaptations
90 in bacteria leading to decreased susceptibility. The risks associated with sub-lethal
91 concentration exposure of bacteria to biocides has been extensively studied.^{18,19} Anti-virulence
92 strategies such as QS inhibition are attractive therapeutic alternatives to antibiotics and biocides
93 due to a perceived mitigation of this selective pressure. However many of these compounds
94 also display bacteriostatic and bactericidal capabilities^{20, 21} and the effects of long-term
95 exposure to QSIs has not been evaluated in bacterial pathogens.

96 The current study therefore aimed to quantify the effects of QSI exposure in eight UPEC
97 isolates. Specifically we will determine impact on antimicrobial and anti-biofilm susceptibility,
98 the induction of antibiotic cross-resistance in addition to changes in biofilm-formation and
99 relative-pathogenicity. With the aim of correlating phenotypic changes with omics data the

100 transcriptome and genome of isolate EC958, a virulent multi-drug resistant strain of UPEC was
101 compared before and after QSI exposure.

102 **Methods**

103 **Bacteria and chemicals.** Six UPEC clinical isolates (EC1, EC2, EC11, EC26, EC28 and
104 EC34) previously isolated from urine during UTI, belonging to the O25:H4-ST131 clone
105 (Stepping Hill Hospital, Stockport, UK) and two laboratory characterised UPEC isolates
106 (EC958 and CFT073) were used in the investigation.²²⁻²⁴ Bacteria were cultured on Muller-
107 Hinton agar (MHA; Oxoid, UK) or in Muller-Hinton broth (MHB; Oxoid, UK) and incubated
108 aerobically at 37 °C for 18 h at 100 rpm. Cinnamaldehyde was purchased from Sigma–Aldrich
109 (Poole, UK). (Z)-4-Bromo-5(bromomethylene)-2(5H)-furanone-C30 (furanone-C30) was
110 synthesised as described previously.²⁵ 4-fluoro-5-hydroxypentane-2,3-dione (F-DPD) was
111 synthesised as described previously.¹³ Furanone-C30, cinnamaldehyde and F-DPD were
112 dissolved at 1 mg/mL in water and filter sterilised prior to use.

113 **Long-term exposure of bacteria to quorum sensing inhibitors.** Bacteria were
114 repeatedly exposed to QSIs using a standardised antimicrobial gradient plating system^{19,24, 26-}
115 ²⁹ adapted from that of McBain *et al.*²⁶ In brief, 100 µL of an MBC concentration solution of
116 QSI was added to an 8- by 8-mm well in the centre of a 90-mm agar plate. Bacterial pure
117 cultures were radially inoculated in triplicate from the edge of the plate to the centre prior to
118 static incubation for 2 days aerobically at 37°C. The biomass from the inner edge of the annulus
119 of bacterial growth, representative of the highest QSI concentration at which growth could
120 occur, was removed and used to inoculate a new QSI-containing plate, as outlined above. This
121 process was repeated for 12 passages (P12). Control isolates passaged 12 times on QSI-free
122 medium were also included (C12). Passaging was performed using three biological replicates

123 for each isolate. Bacteria were archived in 50 % glycerol at -80 °C before and after passage for
124 subsequent testing.

125

126 **Minimum inhibitory and minimum bactericidal concentrations.** MIC and MBC were
127 determined as described previously.²⁷ The MIC was defined as the lowest concentration of QSI
128 for which growth was completely inhibited, determined as a lack of turbidity relative to a sterile
129 negative control. To determine MBC, aliquots (5 µL) were taken from the wells of the MIC
130 plate and were spot plated in triplicate onto Muller Hinton Agar (MHA). The plates were
131 incubated statically for 18 h at 37°C. The lowest test concentration for which visible bacterial
132 growth was completely inhibited was deemed the MBC. Three biological replicates and two
133 technical replicates were performed for each isolate.

134 **Minimum biofilm eradication concentration.** Minimum biofilm eradication
135 concentrations were determined using the Calgary biofilm device (CBD) as described
136 previously.²⁸ MBEC was defined as the lowest concentration of QSI for which re-growth was
137 completely inhibited, viewed as turbidity relative to a sterile negative control. Three biological
138 replicates and two technical replicates were performed for each isolate.

139 **Catheter biofilm model.** Method was adapted from Nweze *et al*,²⁹ catheter sections were
140 cut into segments (1 cm) halved longitudinally and autoclaved. Overnight cultures of bacteria
141 were made in 20 mL MHB, pelleted at 13,000 x g and washed twice in 5 mL PBS and
142 resuspended in 5 mL PBS at OD₆₀₀ 0.18 (10⁷ cells/ml). In a 12 well plate, catheter sections
143 were pre-coated with 4 mL foetal bovine serum (FBS) for 24 h at 37 °C and 30 rpm. FBS was
144 aspirated and 4 mL bacterial suspension was added before incubation for 90 min at 37 °C
145 (adhesion phase). Sections were removed and placed in a 12 well plate containing 4 mL MHB.
146 Plates were incubated for 48 h at 37 °C and 30 rpm (biofilm-formation phase) prior to staining

147 with 3 mL of crystal violet solution at room temperature for 30 minutes. The crystal violet
148 solution was aspirated and sections were gently washed 3 times by submerging in 4 mL of PBS,
149 allowed to air dry for 1 h at room temperature prior to solubilising in 4 mL of 100 % ethanol
150 and determining A_{600} . Two biological replicates and four technical replicates were performed
151 for each isolate. Biofilm formation for the unexposed P0 isolate and the P12 QSI exposed
152 isolates was statistically compared to the control passaged isolate C12 using an ANOVA with
153 post hoc Tukey analysis $p \leq 0.05$.

154 ***Galleria mellonella* pathogenicity assay.** The pathogenesis model was performed as
155 described in Peleg *et al.*³⁰ Final larval-stage *G. mellonella* were obtained from Live Foods
156 Direct, Sheffield, UK. Treated larvae were incubated in a petri dish at 37 °C and the number
157 of surviving individuals was recorded daily. An untreated group and a group injected with
158 sterile PBS were used as controls. The experiment was terminated when at least two individuals
159 in a control group had died or after 7 days of incubation. Two biological replicates were used
160 per isolate to inoculate 12 caterpillars each and significance in death rate was calculated using
161 a log-rank reduction test ($p \leq 0.05$).

162 **Antibiotic susceptibility.** Bacterial susceptibility was determined for trimethoprim
163 sulfamethoxazole (25 µg), nitrofurantoin (50 µg), ciprofloxacin (10 µg), and gentamicin (200
164 µg). Antibiotic susceptibility tests were performed according to the standardized BSAC disc
165 diffusion method for antimicrobial susceptibility testing.³¹ Three biological replicates with two
166 technical repeats were performed for each isolate.

167 **RNA sequencing.** RNA was extracted from 30 mL of a mid-log phase (OD_{600} 0.3)
168 culture of *E. coli* grown in MHB at 37°C and 100 rpm. Three biological replicates were
169 performed for each isolate. RNA was extracted using the TRIzol plus RNA purification kit
170 (Thermofisher, UK). Library preparations, sequencing reactions, and bioinformatic analysis
171 were conducted at GENEWIZ, LLC. (NJ, USA). rRNA depletion was performed using

172 Ribozero rRNA Removal Kit. RNA sequencing library preparation used the NEBNext Ultra
173 RNA Library Prep Kit. Sequencing libraries were validated using the Agilent TapeStation 4200
174 (Agilent Technologies, USA), and quantified by using Qubit 2.0 Fluorometer (Invitrogen, CA).
175 Samples were sequenced using a HiSeq 2x150 Paired End (PE) configuration. Image analysis
176 and base calling were conducted by the HiSeq Control Software (HCS). Data were de-
177 multiplexed using Illumina's bcl2fastq 2.17 software. Sequence reads were trimmed to remove
178 possible adapter sequences and nucleotides with poor quality using Trimmomatic v.0.36. Reads
179 were mapped to the reference genome available using the STAR aligner v.2.5.2b. Unique gene
180 hit counts were calculated by using feature Counts from the Subread package v.1.5.2. DESeq2
181 gave a comparison of gene expression between the sample group. The Wald test was used to
182 generate p-values and Log2 fold-changes. Genes with adjusted p-values < 0.05 and absolute
183 log2 fold-changes > 1 were called as differentially expressed genes for each comparison.
184 Statistical overrepresentation tests were performed using the Fishers exact test to determine
185 significant changes in biological function from sets of differentially expressed genes. This was
186 performed using PANTHER.³²

187 **Genome sequencing**

188 Genome sequencing was performed by MicrobesNG Birmingham, UK. DNA was
189 extracted using a DNeasy kit according to manufacturers instructions (Qiagen, UK). DNA was
190 quantified in triplicates with the Quantit dsDNA HS assay in an Eppendorf AF2200 plate reader.
191 Genomic DNA libraries were prepared using Nextera XT Library Prep Kit (Illumina, San
192 Diego, USA) following the manufacturer's protocol with the following modifications: two
193 nanograms of DNA instead of one were used as input, and PCR elongation time was increased
194 to 1 min from 30 seconds. DNA quantification and library preparation were carried out on a
195 Hamilton Microlab STAR automated liquid handling system. Pooled libraries were quantified

196 using the Kapa Biosystems Library Quantification Kit for Illumina on a Roche light cycler 96
197 qPCR machine. Libraries were sequenced on an Illumina instrument using a 250bp paired end
198 protocol. Reads were adapter trimmed using Trimmomatic 0.30 with a sliding window quality
199 cutoff of Q15.³³ De novo assembly was performed on samples using SPAdes version 3.7,³⁴
200 and contigs were annotated using Prokka 1.11³⁵

201 **Results**

202 **QSI susceptibility of UPEC in planktonic and biofilm states.** MIC, MBC and MBECs
203 were determined for all test isolates before (P0) and after repeated QSI exposure (P12) and
204 were compared to the respective control passaged on QSI free media (C12; Tables 1-3). Control
205 passaged isolate (C12) was also compared to unexposed parent isolate (P0) to ascertain the
206 effects of the passaging procedure alone.

207 After repeated QSI exposure there was a ≥ 2 fold-decrease in MIC in 8/8 isolates for
208 cinnamaldehyde or furanone-C30 indicating an increase in susceptibility compared to their
209 respective passaged controls (C12) (Table 1). There were no significant changes in MIC
210 induced by F-DPD exposure. For MBC (Table 2) QSI exposure led to a ≥ 2 fold-decrease in 8/8
211 isolates for cinnamaldehyde and 6/8 isolates for furanone-C30 when compared to the respective
212 passaged control C12. In contrast 1/8 isolates showed a ≥ 2 fold-increase in MBC after exposure
213 to F-DPD indicating reduced susceptibility. In terms of MBEC (Table 3) there was a ≥ 2 fold-
214 decrease in 8/8 isolates for cinnamaldehyde and 6/8 isolates for furanone-C30 compared to the
215 passaged control (C12). There were no significant changes in MBEC induced by F-DPD
216 exposure.

217 A ≥ 2 -fold decrease in susceptibility was observed at MIC in control passaged isolates (C12)
218 compared to the unexposed parent strains (P0) in 8/8 isolates for both cinnamaldehyde and
219 furanone C30 and in 6/8 for F-DPD. There was a ≥ 2 -fold decrease in susceptibility at MBC in

220 7/8 isolates for cinnamaldehyde, 8/8 for furanone C30 and 6/8 for F-DPD. At MBEC we
221 observed a ≥ 2 fold decrease in susceptibility 8/8 cinnamaldehyde, 3/8 furanone C30 and saw
222 2/8 increases in susceptibility for F-DPD.

223 **The impact of QSI exposure on UPEC biofilm-formation.** Biofilm-formation was
224 determined via a crystal violet biofilm assay for each UPEC isolate before and after repeated
225 QSI exposure (Figure 1). Unexposed isolates displayed varying biofilm forming capabilities
226 prior to exposure with EC1 showing the highest level of biofilm-formation followed by EC26
227 > EC11 > CFT073 > EC958 > EC2 > EC34 and EC28. QSI exposure led to significant ($p \leq$
228 0.05) decreases in biofilm-formation on the catheter surface for 1/8 isolates for cinnamaldehyde
229 (EC34), 3/8 isolates for furanone-C30 (EC28, EC34, EC958) and 3/8 isolates for F-DPD (EC11,
230 EC34 and EC958) when they were compared to their respective passaged controls (C12). When
231 comparing the unexposed parent strain (P0) to the control passaged isolate (C12) an increase
232 in biofilm formation was observed in 5/8 isolates after passaging.

233 **Relative-pathogenicity of UPEC after long-term QSI exposure.** A *G. mellonella*
234 waxworm model was used to determine relative-pathogenicity in UPEC isolates (Figure 2).
235 Data indicate that prior to QSI exposure, EC2 was the least pathogenic and EC1 and EC958
236 were the most pathogenic isolates. Cinnamaldehyde exposure induced significantly (log-rank
237 $p \leq 0.05$) increased relative-pathogenicity in 4/8 isolates (EC2, EC11, EC26, EC28) when
238 compared to the respective control isolate C12. F-DPD exposure induced significantly
239 increased pathogenicity in 2/8 isolates (EC11, EC26) and significantly decreased pathogenicity
240 in 2/8 isolates (EC34, CFT073). Furanone-C30 was the only QSI to induce only significant
241 decreases in pathogenicity which occurred in 6/8 isolates (EC1, EC11, EC26, EC34, EC958,
242 and CFT073). No significant difference in relative pathogenicity was observed when
243 comparing the unexposed parent strain (P0) to the passaged control strain (C12).

244 **Changes in antibiotic susceptibility after QSI exposure.** Isolates were classed as
245 resistant, intermediate, or sensitive to each antibiotic as defined by BSAC breakpoints.³¹
246 Antibiotic susceptibility was determined for UPEC isolates before and after exposure to each
247 QSI (Table 4). Data indicate that cinnamaldehyde exposure induced EC26 to become resistant
248 to gentamicin and EC28 to become intermediately resistant to gentamicin. Exposure to
249 furanone-C30 induced gentamicin resistance in 2/8 isolates (EC26 and EC34) and intermediate
250 resistance in 1 isolate (EC28). F-DPD exposure induced gentamicin resistance in 2/8 isolates
251 (EC26 and EC28). Cinnamaldehyde exposure induced CFT073 to become intermediately
252 resistant to trimethoprim sulfamethoxazole as did furanone-C30 exposure. There were cases
253 where isolates that were initially resistant to trimethoprim sulfamethoxazole became more
254 susceptible after QSI exposure. This occurred in EC2 after exposure to furanone-C30 and F-
255 DPD. This was also observed in EC28 for ciprofloxacin after cinnamaldehyde and F-DPD
256 exposure. There was no observed change in BSAC classification of susceptibility in the control
257 C12 isolate when compared to the unpassaged parent strain P0.

258 **Alterations in EC958 genome and transcriptome after QSI exposure.**

259 Variant analysis of the EC958 genome was performed after long-term QSI exposure
260 (P12) or repeated passage in a QSI free environment (C12) relative to an unexposed parent
261 strain (P0, Table 5). Exposure to cinnamaldehyde selected for a mutation in RNA chaperone
262 *proQ* and *dnaX* encoding the tau subunit of DNA polymerase III. Mutations in a DUF2931
263 family protein of unknown function were acquired after exposure to all QSIs in addition to the
264 control passage isolate. Silent mutations in *entS*, part of the EntS/YbdA MFS enterobactin
265 transporter system were observed after cinnamaldehyde or furanone exposure and in the control
266 passaged isolate.

267 Transcriptomic data comparing the QSI exposed bacteria (P12) to the passage control
268 (C12), allowing us to determine the effect of QSI exposure whilst controlling for passaging,
269 showed the following; during cinnamaldehyde exposure 368 genes were significantly ($p \leq 0.05$)
270 upregulated and 329 genes were significantly downregulated. GO enrichment analysis of
271 biological function (Table 6) showed a significant downregulation in locomotion (25 genes),
272 chemotaxis (15 genes), bacterial flagellum associated motility (14 genes) and reactive nitrogen
273 species metabolic processes (16). An increase in the expression of genes associated with toxin
274 biosynthetic processes (7 genes), drug catabolic processes (24 genes) and responses to stress
275 (91 genes, Table 6) was observed after cinnamaldehyde exposure. Notably there was a
276 substantial decrease in genes associated with flagellar synthesis and function (*fliCDFGKMNS*,
277 *flgCGK* and *motA*), chemotaxis (*cheABRWYZ*), cell wall synthesis associated proteins (*mltB*,
278 *flgJ* and *lysM*), iron sulphur cluster synthesis (*sufC*) and multidrug efflux transporter systems
279 (*acrAB* and *mdtEF* Table S1). We observed an increase in the expression of genes encoding
280 fimbrial-like adhesin and associated outer membrane usher proteins *yehB* and *yehD*, a *fimA*
281 homologue, and in afimbrial adhesin associated proteins *afaD* and *afaC* (Table S1).

282 Similarly, exposure to F-DPD caused a significant downregulation in locomotion-related genes
283 with 25 genes differentially expressed including those associated with the flagellum assembly
284 and motility (*fliCDFGHKMNS*, *flgCHJ* and *motA*) and chemotaxis (*cheABRWYZ*; Table 6 and
285 Table S1). Multidrug efflux transporter system *mdtEF* was downregulated and afimbrial
286 adhesin associated proteins *afaC* *afaD* and *afaE* were upregulated (Table S1). Exposure to
287 Furanone-C30 led to a significant reduction in a large number of genes associated with
288 translation (34 genes) including ribosomal small (9 genes) and large (13 genes) subunit
289 assembly (Table 6, Table S1). There was an increase in gene expression associated with IMP
290 biosynthetic processes (7 genes), reactive nitrogen species metabolic processes (7 genes), drug
291 catabolic processes (10 genes) and carbohydrate catabolic processes (14 genes, Table 6).

292 Separately, to determine the effect of passaging, when comparing the control passaged isolate
293 C12 to the unexposed parent strain (P0) increases in expression of genes associated with
294 ribosome assembly (19 genes), cellular biosynthetic processes (156 genes) and cellular
295 respiration (33 genes) were observed as was a decreases in expression of genes associated with
296 reactive nitrogen species metabolic processes (10 genes) (Table 6, Table S1).

297 **Discussion**

298 **QSI exposure induces changes in susceptibility in planktonic UPEC.** Exposure of
299 UPEC to a panel of QSI's was performed using a gradient plating system.²⁴ Cinnamaldehyde
300 induced a high frequency of >2-fold increases in susceptibility at MIC, MBC, and MBEC
301 (Tables 1 and 2). Cinnamaldehyde has been previously shown to cause oxidative damage to
302 and alter the fatty acid composition of the *E. coli* cell membrane.³⁶⁻³⁷ This may have
303 compromised the structural integrity of the membrane and increased cell permeability,
304 providing a possible mechanism for the observed increase in susceptibility. RNA sequencing
305 of the cinnamaldehyde exposed EC958 strain revealed a downregulation of *sufC* which is
306 involved in iron-sulphur cluster synthesis³⁸ (Table S1). Decreased SufC activity has been
307 shown to cause increased susceptibility to ROS and DNA damage in certain bacteria.³⁸ As
308 cinnamaldehyde's mechanism of action depends on oxidative damage³⁷ a decrease in SufC
309 production may explain the increase in cinnamaldehyde susceptibility. Furthermore, there was
310 a reduction in cellular efflux systems *acrAB* and *mdtEF* and cell wall synthesis associated
311 proteins *mltB*, *flgJ* and *lysM* which may culminate in increased cell wall permeability and a
312 reduction in efflux-mediated defence (Table 6, Table S1).

313 There were increases in susceptibility for all of the UPEC isolates when exposed to furanone-
314 C30 at MIC level and 6 increases observed at MBC (Table 1-2). There is minimal previous
315 report of the response of *E. coli* to furanone-C30 outside its immediate inhibitory influence on

316 QS and biofilm-formation.³⁹ The furanone exposed EC958 isolate was observed to have
317 significantly decreased expression of *mltA*, a murein transglycosylase, which plays a role in
318 enlargement of the murein sacculus⁴⁰ (Table S1). Impairment of sacculus formation could lead
319 to a loss in cell integrity and increased cell permeability leading to increased antimicrobial
320 susceptibility. The control passaged isolate (C12) showed decreased antimicrobial
321 susceptibility when compared to the unexposed parent strain (P0) this may be due to an
322 observed reduction in porin expression (*ompF* and *ompC*) impairing diffusion of QSIs across
323 the membrane and subsequent interaction with intracellular targets (Table S1).

324 **Biofilm-formation and susceptibility in UPEC after QSI exposure.** QS in *E. coli* is
325 mediated by AI-2 and it has been shown that AI-2 production is directly correlated to biofilm-
326 formation and motility.¹⁰ Cinnamaldehyde is considered to interfere in AI-2 based signaling
327 and can reportedly further disrupt biofilm-formation by reduced accumulation of EPS.⁴¹ There
328 was an increase in biofilm susceptibility for all isolates after cinnamaldehyde exposure in the
329 current investigation (Table 3) which correlated with a decrease in biofilm-formation for 1/8
330 isolates on the catheter surface (Figure 1). In a previous study cinnamaldehyde exposure caused
331 an increase in biofilm cell signaling protein *bhsA* and type-1 fimbriae after 4 h.⁴² In our study,
332 we found an upregulation of fimbrial like adhesin *yehB*, a *fimA* homologue, and upregulation
333 of fimbrial outer membrane usher protein *yehD* (Table S1). We also observed an increase in
334 afimbrial adhesin associated proteins *afaD* and *afaC*. There was a decrease in numerous genes
335 associated with flagella synthesis, motility and chemotaxis in addition to transcriptional
336 activator *csgD*, which controls cellulose and curli biosynthesis⁴³ (Table 6, Table S1). Variant
337 analysis of the EC950 genome after cinnamaldehyde exposure revealed a mutation in RNA-
338 binding protein ProQ which plays a role in small RNA-mediated control of gene expression in
339 bacteria (Table 5). ProQ mutation has been shown to decrease expression of a number of
340 flagella associated proteins in extracellular *Salmonella enterica* serovar Typhimurium although

341 the role in *E. coli* is not fully understood.⁴⁴ A reduction in motility and impaired cellulose
342 synthesis may reduce biofilm initiation, EPS production and maturation. This would explain
343 the decreases in biofilm-formation and increases in biofilm susceptibility observed in the
344 cinnamaldehyde adapted UPEC isolates.

345 After furanone-C30 exposure small magnitude increases in biofilm susceptibility were
346 observed in 6/8 isolates (Table 3) whilst biofilm-formation decreased for 3/8 isolates (Figure
347 1). *E. coli* biofilm-formation has been shown previously to be inhibited by furanone-C30^{15, 45}
348 partially due to a down regulation in genes associated with chemotaxis, flagellar synthesis, and
349 motility. We did not, however, find significant downregulation of genes associated with these
350 processes in furanone adapted EC958 but did see downregulation in a number of genes
351 associated with translation initiation and cellular biosynthetic processes which may directly
352 impact growth rate (Table 6).

353 F-DPD is an analogue of AI-2 and inhibits QS by competitively blocking the AI-2 receptor.¹³
354 In the current study, exposure to F-DPD did not induce any change in biofilm susceptibility
355 however we observed a reduction in biofilm-formation in 3/8 isolates on the catheter surface
356 (Table 3, Figure 1). After F-DPD adaptation there was a reduction in flagellar synthesis and
357 motility associated genes including *fliCDFGHKMNS*, *flgCHJ* and *motA* (Table 6, Table S1).
358 This reduction in motility would impair biofilm initiation and may result in the decrease in
359 biofilm-formation observed in the F-DPD adapted isolates.

360 The observed increase in biofilm formation observed when comparing control passaged strain
361 (C12) to the unexposed parent isolate (P0) is likely due to the observed increase in cellular
362 respiration enhancing growth, cellular biosynthesis and therefore replicative potential during
363 biofilm establishment (Table 6, Figure 1). Increased biofilm formation may consequently lead

364 to a reduction in biofilm susceptibility, which may be further exacerbated by reduced porin
365 expression on a cellular level (Table 3, Table 6, Table S1).

366 **Changes in antibiotic susceptibility after QSI exposure in UPEC.** Decreased
367 susceptibility to antibiotics resulting in a change in BSAC classification occurred in 9 out of a
368 possible 63 cases (Table 4). Increased antibiotic susceptibility where resistance was reversed
369 to a susceptible or intermediate classification occurred in 4 out of a possible 33 cases (Table
370 4). Previous studies have shown that exposure to cinnamaldehyde upregulated the expression
371 of several antibiotic resistance genes including *marRAB* and *mdtEF* in *E. coli*.⁴² We also
372 observed overexpression of *marA* in the cinnamaldehyde exposed EC958 isolate in addition to
373 upregulation of *mdtN* (Table S1) which has been associated with multidrug resistance
374 previously however isolate EC958 did not show induced antibiotic resistance after QSI
375 exposure.⁴² Furanone-C30 exposure resulted in an overall reduction in biosynthetic processes
376 within the bacterial cell which may contribute towards some of the antibiotic insusceptibility
377 observed in our UPEC isolates. Treatment with F-DPD has been previously shown to increase
378 rifampicin resistance in *E. coli* due to an increase in mutation rate plasticity via increased
379 modulation of mutational hotspots by Dam methylase¹⁴ which may confer a generalised
380 mechanism of resistance towards different antibiotics. In the current investigation, there were
381 4 cases where QSI exposure led to increase in the susceptibility of isolates (EC2 and EC28) to
382 certain antibiotics (trimethoprim and ciprofloxacin). Antibiotic cross-protection after
383 antimicrobial exposure has been demonstrated previously²⁷⁻²⁸, and is theorised to be caused
384 due to a generalised increased cellular permeability. Variant analysis of EC958 genomes
385 indicated that we did not select for any mutations that have been previously associated with
386 mechanisms of resistance towards the tested antibiotics.

387 **Altered relative-pathogenicity in QSI adapted UPEC.** Virulence factors that influence
388 biosynthesis, motility, surface adhesion and toxin production have been shown to be regulated

389 by QS in *E. coli*.⁴⁶ Long-term exposure to cinnamaldehyde induced increased pathogenicity in
390 4 UPEC isolates which may be due to an increase in adhesin associated proteins *yehB*, *yehD*,
391 *afaD* and *afaC* facilitating cell entry (Table S1). Furanone-C30 was the only QSI to induce
392 only decreases in pathogenicity which occurred in 6/8 isolates (Figure 2). Furanone-C30 has
393 been shown to repress major virulence factors such as proteasases *lasA* and *lasB*, chitinase
394 (*chiC*), and pyocyanine synthesis *phzABCDEFG* in *P. aeruginosa*,⁴⁷ but there is no previously
395 reported impact on virulence factor production in UPEC. RNA sequencing of EC958 revealed
396 a reduction in a number of translation associated proteins and a resulting decrease in
397 biosynthetic processes within the cell which may impair replication and thus survival within
398 the waxworm model, however we did not identify change in regulation of any specific
399 virulence factors from our DE gene expression data after furanone-C30 exposure. Both
400 increases and decreases in relative-pathogenicity were observed in 2/8 isolates when exposed
401 to F-DPD but this did not occur in EC958.

402 **Conclusion**

403 Quorum sensing inhibitors (QSIs) are a novel class of anti-biofilm agents that due to their site
404 specific nature and low level cytotoxicity are being widely considered as promising anti-
405 infective medical device coating agents. However unlike broad-spectrum antimicrobials such
406 as biocides, their long-term effects remain largely unknown. Here we report, the impact of
407 adaptation towards three QSIs in a panel of UPEC. Planktonic susceptibility (MIC and MBC)
408 increased for cinnamaldehyde and furanone-C30 whilst remaining unchanged for F-DPD.
409 Changes in susceptibility were correlated to reductions in cellular efflux and an increase in cell
410 wall permeability. Biofilm-formation and susceptibility frequently decreased or remained
411 unchanged after long-term QSI exposure possibly due to a downregulation of motility and
412 chemotaxis associated systems for cinnamaldehyde and furanone-C30. Relative-pathogenicity
413 largely increased for cinnamaldehyde exposed isolates whilst decreasing after Furanone-C30

414 exposure and showing a strain specific response for F-DPD. Concerningly, we observed the
415 emergence of antibiotic resistance after QSI exposure in a 9/63 UPEC isolates. These data
416 highlight that in order to understand the long-term effects of anti-virulence strategies such as
417 QSIs multiple phenotypic effects need to be assessed in relevant bacterial pathogens.

418 **Acknowledgements**

419 The authors thank the medical microbiology and virology unit at The University of Manchester
420 for donating the UPEC clinical isolates. Genome sequencing was provided by MicrobesNG
421 (<http://www.microbesng.uk>).

422 **Funding**

423 This work was supported by the Biomolecular Sciences Research Centre, Sheffield Hallam
424 University

425 **Transparency declarations**

426 None to declare

427 **References**


- 428 1. Plowman R, Graves N, Esquivel J *et al.* An economic model to assess the cost and
429 benefits of the routine use of silver alloy coated urinary catheters to reduce the risk of urinary
430 tract infections in catheterized patients. *J Hosp Infect* 2001; **48**: 33-42.
- 431 2. Jacobsen SM, Stickler DJ, Mobley HLT *et al.* Complicated catheter-associated urinary
432 tract infections due to *Escherichia coli* and *Proteus mirabilis*. *Clin Microbiol Rev* 2008; **21**:
433 26-59.
- 434 3. MacIntyre CR, Bui CM. Pandemics, public health emergencies and antimicrobial
435 resistance - putting the threat in an epidemiologic and risk analysis context. *Arch Public Health*
436 2017; **75**: 1-6.
- 437 4. Singha P, Locklin J, Handa H. A review of the recent advances in antimicrobial coatings
438 for urinary catheters. *Acta Biomater* 2017; **50**: 20-40.
- 439 5. Braoudaki M, Hilton, AC. Low level of cross-resistance between triclosan and
440 antibiotics in *Escherichia coli* K-12 and *E. coli* O55 compared to *E. coli* O157. *FEMS*
441 *Microbiol Lett* 2004; **235**: 305-9.
- 442 6. Brackman G, Coenye T. Quorum sensing inhibitors as anti-biofilm agents. *Curr Pharm*
443 *Des* 2015; **21**: 5-11.

- 444 7. Bjarsholt T, Denmark KUKN. The role of bacterial biofilms in chronic infections.
445 *APMIS* 2016; **121**: 1-58.
- 446 8. Pappenfort K, Bassler B. Quorum-Sensing Signal-Response Systems in Gram-Negative
447 Bacteria. *Nat Rev Microbiol* 2016; **14**: 576-88.
- 448 9. Hardie KR, Heurlier K. Establishing bacterial communities by 'word of mouth': LuxS
449 and autoinducer 2 in biofilm development. *Nature Rev Microbiol* 2008; **8**: 635-43.
- 450 10. Gonzalez Barrios AF, Zuo R, Hashimoto Y *et al.* Autoinducer 2 controls biofilm-
451 formation in *Escherichia coli* through a novel motility quorum-sensing regulator (MqsR,
452 B3022). *J Bacteriol* 2006; **188**: 305-16.
- 453 11. Neiditch MB, Federle MJ, Miller ST *et al.* Regulation of LuxPQ receptor activity by
454 the quorum-sensing signal autoinducer-2. *Mol Cell* 2005; **18**: 507-18.
- 455 12. Roy V, Meyer MT, Smith JA *et al.* AI-2 analogs and antibiotics: a synergistic approach
456 to reduce bacterial biofilms. *Appl Microbiol Biotech* 2013; **97**: 2627-38.
- 457 13. Kadirvel M, Forbes S, McBain AJ *et al.* Inhibition of quorum sensing and biofilm-
458 formation in *Vibrio harveyi* by 4-fluoro-DPD; a novel potent inhibitor of signalling. *Chem*
459 *Commun* 2014; **50**: 5000-2.
- 460 14. Krasovec R, Belavkin RV, Aston JA *et al.* Mutation rate plasticity in rifampicin
461 resistance depends on *Escherichia coli* cell-cell interactions. *Nat Commun* 2014; **5**: 3742.
- 462 15. Ren D SJ, Wood TK. Inhibition of biofilm-formation and swarming of *Escherichia coli*
463 by (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone. *Environ Microbiol* 2001; **3**:
464 731-6.
- 465 16. Niu C, Afre S, Gilbert ES. Subinhibitory concentrations of cinnamaldehyde interfere
466 with quorum sensing. *Lett Appl Microbiol* 2006; **43**: 489-94.
- 467 17. Amalaradjou MA, Narayanan A, Venkitanarayanan K. Trans-cinnamaldehyde
468 decreases attachment and invasion of uropathogenic *Escherichia coli* in urinary tract epithelial
469 cells by modulating virulence gene expression. *J Urol* 2011; **185**: 1526-31.
- 470 18. McDonnell GE. Antisepsis, disinfection, and sterilization: types, action, and resistance.
471 Washington, DC.: ASM Press 2007.
- 472 19. Forbes S, Knight CG, Cowley NL *et al.* Variable effects of exposure to formulated
473 microbicides on antibiotic susceptibility in firmicutes and proteobacteria. *Appl Environ*
474 *Microbiol* 2016; **82**: 3591-8.
- 475 20. Firmino DF, Cavalcante TTA, Gomes GA *et al.* Antibacterial and antibiofilm activities
476 of cinnamomum Sp. essential oil and cinnamaldehyde: Antimicrobial activities. *Sci World J*
477 2018;7405736.
- 478 21. Ren D, Bedzyk LA, Setlow, P *et al.* Differential gene expression to investigate the
479 effect of (5Z)-4-bromo- 5-(bromomethylene)-3-butyl-2(5H)-furanone on *Bacillus subtilis*.
480 *Appl Environ Microbiol* 2004; **70**: 4941-9.
- 481 22. Lau SH, Reddy S, Cheesbrough J *et al.* Major uropathogenic *Escherichia coli* strain
482 isolated in the northwest of England identified by multilocus sequence typing. *J Clin*
483 *Microbiol* 2008; **46**:1076-1080.
- 484 23. Lau SH, Kaufmann ME, Livermore DM *et al.* UK epidemic *Escherichia coli* strains A-
485 E, with CTX-M-15 β -lactamase, all belong to the international O25: H4-ST131 clone. *J*
486 *Antimicrobial Chemother* 2008; **62**:1241-1244.
- 487 24. Henly E, Dowling, JAR, Maingay, JB *et al.* Biocide Exposure Induces Changes in
488 Susceptibility, Pathogenicity and Biofilm-formation in Uropathogenic *Escherichia coli*.
489 *Antimicrob Agents Chemother* 2019; **63**.3
- 490 25. Guo JL, Li BZ, Chen WM *et al.* Synthesis of Substituted 1H-Pyrrol-2(5H)-ones and
491 2(5H)-Furanones as Inhibitors of *P. aeruginosa* Biofilm. *Lett drug des discov* 2009; **6**.107-113.

- 492 26. McBain AJ, Ledder RG, Moore LE *et al.* Effects of quaternary-ammonium-based
493 formulations on bacterial community dynamics and antimicrobial susceptibility. *Appl Environ*
494 *Microbiol* 2004; **70**: 3449-56.
- 495 27. Forbes S, Latimer J, Bazaid A *et al.* Altered competitive fitness, antimicrobial
496 susceptibility, and cellular morphology in a triclosan-induced small-colony variant of
497 *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2015; **59**: 4809-16.
- 498 28. Cowley NL, Forbes S, Amezquita A *et al.* Effects of formulation on microbicide
499 potency and mitigation of the development of bacterial insusceptibility. *Appl Environ*
500 *Microbiol* 2015; **81**: 7330-8.
- 501 29. Nweze EI, Ghannoum A, Chandra J *et al.* Development of a 96-well catheter-based
502 microdilution method to test antifungal susceptibility of *Candida* biofilms. *J Antimicrob*
503 *Chemother* 2012; **67**: 149-53.
- 504 30. Peleg AY, Monga D, Pillai S *et al.* Reduced susceptibility to vancomycin influences
505 pathogenicity in *Staphylococcus aureus* infection. *J Infect Dis* 2009; **199**: 532-6.
- 506 31. Andrews JM, BSAC Working Party on Susceptibility Testing ft. BSAC standardized
507 disc susceptibility testing method. *J Antimicrob Chemother* 2017; **48**: 43-57.
- 508 32. Mi H, Muruganujan A, Ebert D *et al.* PANTHER version 14: more genomes, a new
509 PANTHER GO-slim and improvements in enrichment analysis tools. *Nucleic Acids Res* 2019;
510 **47**: D419-D26.
- 511 33. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence
512 data. *Bioinformatics* 2015; **30**:114–2120.
- 513 34. Bankevich A, Nurk S, Antipov D. SPAdes: A new genome assembly algorithm and its
514 applications to single-cell sequencing. *J Comp Biol* 2012; **19**:455–477.
- 515 35. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 2014; **30**:2068-
516 9.
- 517 36. He TF, Zhang ZH, Zeng XA *et al.* Determination of membrane disruption and genomic
518 DNA binding of cinnamaldehyde to *Escherichia coli* by use of microbiological and
519 spectroscopic techniques. *J Photochem Photobiol B* 2018; **178**: 623-30.
- 520 35. He TF, Wang LH, Niu DB, *et al.* Cinnamaldehyde inhibit *Escherichia coli* associated
521 with membrane disruption and oxidative damage. *Arch Microbiol* 2018; **201**:451-58.
- 522 36. Roberts CA, Al-Tameemi HM, Mashruwala AA *et al.* The Suf iron-sulfur cluster
523 biosynthetic system is essential in *Staphylococcus aureus*, and decreased Suf function results
524 in global metabolic defects and reduced survival in human neutrophils. *Infect Immun* 2017; **85**:
525 e00100-17.
- 526 37. Worthington RJ, Richards, JJ, Melander C. Small molecule control of bacterial biofilms.
527 *Org Biomol Chem* 2012; **10**: 7457-74.
- 528 38. van Straaten KE, Dijkstra BW, Vollmer W *et al.* Crystal structure of MltA from
529 *Escherichia coli* reveals a unique lytic transglycosylase fold. *J Mol Biol* 2005; **352**: 1068-80.
- 530 39. Brackman G, Defoirdt T, Miyamoto C *et al.* Cinnamaldehyde and cinnamaldehyde
531 derivatives reduce virulence in *Vibrio* spp. by decreasing the DNA-binding activity of the
532 quorum sensing response regulator LuxR. *BMC Microbiol* 2008; **8**: 149.
- 533 40. Visvalingam J, Hernandez-Doria JD, Holley RA *et al.* Examination of the genome-wide
534 transcriptional response of *Escherichia coli* O157:H7 to cinnamaldehyde exposure. *Appl*
535 *Environ Microbiol* 2013; **79**: 942-50.
- 536 41. Monteiro C, Saxena I, Wang X *et al.* Characterization of cellulose production in
537 *Escherichia coli* Nissle 1917 and its biological consequences. *Environ Microbiol* 2009; **11**:
538 1105-16.
- 539 42. Vestby LK, Johannesen KCS, Witsø IL *et al.* Synthetic brominated furanone F202
540 prevents biofilm-formation by potentially human pathogenic *Escherichia coli* O103:H2 and
541 *Salmonella ser. Agona* on abiotic surfaces. *J Appl Microbiol* 2014; **116**: 258-68.

- 542 **43.** Ulett GC, Valle J, Beloin C *et al.* Functional analysis of antigen 43 in uropathogenic
543 *Escherichia coli* reveals a role in long-term persistence in the urinary tract. *Infect Immun* 2007;
544 **75**: 3233-44.
- 545 **44.** Westermann AJ, Venturini E, Sellin ME *et al.* The major RNA-binding protein ProQ
546 impacts virulence gene expression in salmonella enterica serovar typhimurium. *MBio* 2019;
547 **10.1**.
- 548 **45.** Miryala SK, Ramaiah S. Exploring the multi-drug resistance in *Escherichia coli*
549 O157:H7 by gene interaction network: A systems biology approach. *Genomics* 2019; **111**: 958-
550 65.
- 551 **46.** Antunes LC, Ferreira RB, Buckner MM *et al.* Quorum sensing in bacterial virulence.
552 *Microbiology (Reading, England)* 2010; **156**: 2271-2282.
- 553 **47.** Hentzer M, Wu H, Andersen JB *et al.* Attenuation of *Pseudomonas aeruginosa*
554 virulence by quorum sensing inhibitors. *EMBO J* 2003; **22**: 3803-15.
- 555
- 556

557 Figure 1: Biofilm-formation in QSI adapted UPEC




558

559

560 Figure 1: Crystal violet biofilm assay indicating the effect of long-term QSI exposure on
561 biofilm-formation in eight isolates of UPEC. Data show the mean absorbance (A_{600})
562 representative of biofilm-formation for the following isolates; Unexposed parental isolate (P0)
563 that has not undergone passage. Cinnamaldehyde, furanone-C30 or F-DPD exposed isolate
564 (P12): which has undergone 12 passages in the presence of named QSI. Control (C12) which has
565 undergone 12 passages on a QSI free media. Data represent samples taken from two biological
566 replicates each with four technical repeats. For data that varied between replicates, SDs are
567 given as error bars. Significance was determined using ANOVA with a post hoc Tukey
568 analysis; * $p \leq 0.05$ when comparing the unexposed isolate (P0) or a QSI passaged isolate to the
569 respective control C12.

570

571 Figure 2: Relative-pathogenicity of QSI adapted UPEC



572

573 Figure 2: *G. mellonella* survival curves for larvae injected with QSI-exposed and -unexposed
 574 UPEC. Control data from non-injected larvae, larvae injected with PBS alone, and larvae
 575 injected with control isolates passaged on a QSI free media (Control) are also shown. *
 576 indicates a significant difference in pathogenicity when comparing QSI adapted isolates to the
 577 respective passaged control strain ($p \leq 0.05$, log-rank reduction test $n=24$).

578 Table 1: Minimum inhibitory concentrations for UPEC before and after QSI exposure.

Isolate	Cinnamaldehyde			Furanone-C30			F-DPD		
	P0	P12	C12	P0	P12	C12	P0	P12	C12
EC1	250	125	500	125	125	500	125	125	125
EC2	250	250	500	125	125	375 (144)	125	125	125
EC11	250	250	500	125	125	375 (144)	62.5	125	125
EC26	250	125	500	125	125	313 (125)	62.5	125	125
EC28	250	250	500	125	125	500	62.5	125	125
EC34	250	250	500	125	125	313 (125)	62.5	125	125
EC958	250	250	500	125	125	375 (144)	62.5	125	125
CFT073	250	250	500	125	125	250	125	250	250

579

580 Minimum inhibitory concentrations (mg/L) for UPEC before exposure (P0), after 12 passages
 581 in the presence of each QSI (P12) or after 12 passages in a QSI free environment (C12). Data
 582 represent mean MICs taken from three biological replicates each with two technical repeats.
 583 SDs are given in parentheses. Data \geq 2-fold-change in susceptibility are highlighted in bold
 584 when comparing the QSI passaged isolates to the respective passaged control (C12).

585

586

587

588

589

590

591 Table 2: Minimum bactericidal concentrations for UPEC before and after QSI exposure.

Isolate	Cinnamaldehyde			Furanone-C30			F-DPD		
	P0	P12	C12	P0	P12	C12	P0	P12	C12
EC1	1000	500	1750 (500)	250	250	500	250	500	500
EC2	1000	1000	2000	250	125	500	250	500	500
EC11	250	1000	2000	125	250	437.5 (125)	250	500	500
EC26	250	1000	2000	125	125	375 (144)	250	250	250
EC28	250	1000	2000	250	125	500	250	500	500
EC34	250	1000	2000	125	125	312.5 (125)	250	250	125
EC958	250	1000	2000	250	250	375 (144)	250	500	500
CFT073	250	250	1250 (500)	125	125	250	250	500	500

592

593 Minimum bactericidal concentrations (mg/L) for UPEC before exposure to QSI (P0), after 12
 594 passages in the presence of each QSI (P12), and after 12 passages in a QSI free environment
 595 (C12). Data represent mean MBCs taken from three biological replicates each with two
 596 technical repeats. SDs are given in parentheses. Data \geq 2-fold-change in susceptibility are
 597 highlighted in bold when comparing the QSI passaged isolates to the respective passaged
 598 control (C12).

599

600

601

602

603

604

605

606 Table 3: Minimum biofilm eradication concentrations for UPEC before and after QSI exposure.

Isolate	Cinnamaldehyde			Furanone-C30			F-DPD		
	P0	P12	C12	P0	P12	C12	P0	P12	C12
EC1	250	250	1000	250	250	312.5 (125)	500	500	500
EC2	250	250	1000	250	250	437.5 (125)	250	250	250
EC11	250	250	500	125	125	437.5 (375)	62.5	15.6	15.6
EC26	250	250	1000	125	250	500	250	250	250
EC28	250	250	1000	250	125	500	500	250	250
EC34	250	250	1000	125	93.75 (44.2)	187.5 (72.2)	62.5	62.5	62.5
EC958	250	250	1000	250	125	500	500	500	500
CFT073	250	250	500	250	125	250	500	500	500

607

608 Minimum biofilm eradication concentrations (mg/L) for UPEC before exposure to QSI (P0),
609 after 12 passages in the presence of each QSI (P12), and after 12 passages in a QSI free
610 environment (C12). Data represent mean MBECs taken from three biological replicates each
611 with two technical repeats . SDs are given in parentheses. Data \geq 2-fold-change in susceptibility
612 are highlighted in bold when comparing the QSI passaged isolates to the respective passaged
613 control (C12).

614 Table 4: Antibiotic susceptibility of UPEC before and after QSI exposure

Antibiotic	Exposure	EC1	EC2	EC11	EC26	EC28	EC34	EC958	CFT073
Trimethoprim Sulfamethoxazole	Unexposed (P0)	14.4 (1.8) S	0 R	0 R	0 R	0 R	0 R	0 R	15.3 (1) S
	Control (C12)	14.5 (0.8) S	0 R	0 R	0 R	0 R	0 R	0 R	15.1 (0.8) S
	Cinnamaldehyde (P12)	14.3 (0.8) S	11 (5.5) R	0 R	0 R	0 R	0 R	0 R	12.8 (1.9) I
	Furanone-C30 (P12)	14.2 (1.5) S	11.3 (1.4) I	0 R	0 R	0 R	0 R	0 R	13 (3.5) I
	F-DPD (P12)	29.7 (0.5) S	29 (0.6) S	0 R	3.7 (4) R	0 R	0 R	0 R	36.7 (0.8) S
Nitrofurantoin	Unexposed (P0)	20.3 (0.3) S	20.7 (0.3) S	23.7 (0.3) S	21.2 (1.5) S	19.7 (0.5) S	16.3 (1.2) S	20.4 (1.4) S	18 (0.6) S
	Control (C12)	20.5 (0.2) S	20.3 (0.5) S	22.3 (0.5) S	21.3 (1.3) S	18.1 (0.4) S	16.1 (0.8) S	20.2 (0.5) S	18.2 (0.7) S
	Cinnamaldehyde (P12)	23 (1) S	22.3 (1.5) S	26.7 (1.2) S	25 (1) S	20.3 (4.7) S	18 (3) S	20.7 (0.6) S	22 (1) S
	Furanone-C30 (P12)	24 (1) S	24.7 (0.6) S	22.3 (0.6) S	21.7 (0.6) S	18.3 (2.1) S	17.3 (0.6) S	19.7 (1.5) S	17.7 (2.3) S
	F-DPD (P12)	22.3 (0.6) S	24.7 (0.6) S	23.7 (1.2) S	26.3 (2.5) S	19.3 (0.6) S	18.7 (1.5) S	21.7 (2.1) S	19.7 (0.6) S
Ciprofloxacin	Unexposed (P0)	33 (0.6) S	0 R	0 R	0 R	25 (0.9) I	0 R	0 R	35 (1.3) S
	Control (C12)	34.2 (0.4) S	0 R	0 R	0 R	25 (0.4) I	0 R	0 R	34.2 (1.2) S
	Cinnamaldehyde (P12)	35.5 (0.8) S	0 R	0 R	0 R	29 (1.3) S	1.7 (4.1) R	0 R	33.3 (1) S
	Furanone-C30 (P12)	29.9 (1) S	0 R	0 R	0 R	25 (2.5) I	0 R	0 R	32.2 (1.2) S
	F-DPD (P12)	33 (1.3) S	0 R	0 R	0 R	27.5 (1.4) S	0 R	0 R	47.7 (2.5) S
Gentamicin	Unexposed (P0)	26 (0.5) S	27.7 (0.3) S	25.5 (0.6) S	14.3 (1.2) I	18.2 (1) S	16.5 (0.5) I	26 S	24.8 (0.4) S
	Control (C12)	24.3 (1.2) S	23.7 (1.1) S	24.9 (0.3) S	14.5 (0.8) I	18.0 (0.7) S	15.6 (0.7) I	25 (0.8) S	23.7 (0.2) S
	Cinnamaldehyde (P12)	20.2 (0.8) S	20.2 (1) S	20.2 (1) S	12.3 (0.8) R	15 I	14.3 (0.8) I	20 S	21.8 (1.8) S
	Furanone-C30 (P12)	19 (1.1) S	19.8 (0.4) S	20 S	11 (0.9) R	14.5 (0.8) I	13.3 (1.5) R	20.7 (1.6) S	23.9 (2.1) S
	F-DPD (P12)	17.5 (0.5) S	19 (0.6) S	19 (0.9) S	13.7 (0.5) R	13.3 (0.8) R	14.3 (0.8) I	19.2 (1) S	23 (1.7) S

615 Data show the mean antibiotic inhibition zones (mm) for UPEC before and after QSI exposure (mm) and represent samples taken from three
616 separate experiments each with two technical replicates. For data that varied between replicates, SDs are given in parentheses. S = Sensitive, I =

617 Intermediate, R = Resistant, as defined by BSAC breakpoint. Where isolates changed from susceptible to intermediate or resistant after QSI
618 exposure or from resistant to intermediate or susceptible this is highlighted in bold.

619

620

621

622

623

624

625

626

627

628

629

630

631

632 Table 5: Variant Analysis of QSI adapted EC958 genomes.

Product	Locus Tag	Position	Mutation Type	Protein ID	Isolate
Manganese efflux pump	<i>mntP</i>	281462	Silent	WP_001296134.1	Fur
RNA chaperone	<i>proQ</i>	290547	Nonsense	WP_000431388.1	Cin
DUF2931 family protein	21883_Unexposed_00512	1165	Missense	WP_059319623.1	Cin, DPD, Fur, Con
DUF2931 family protein	21883_Unexposed_00512	1184	Silent	WP_059319623.1	Cin, DPD, Fur
DUF2931 family protein	21883_Unexposed_00512	1232	Silent	WP_059319623.1	Cin
DNA polymerase III subunit Tau	<i>dnaX</i>	274099	Missense	WP_000122044.1	Cin
EntS/YbdA MFS transporter	21883_Unexposed_04281	302	Silent	WP_113417725.1	Cin
EntS/YbdA MFS transporter	21883_Unexposed_04281	1844	Silent	WP_113417725.1	Cin, Fur, Con

633

634 Effects of long-term exposure to QSIs on the genome sequence in EC958, data shows variant analysis of QSI exposed isolates (P12) and control
635 passaged isolate (C12) compared to unexposed parent strain (P0).

636 Table 6: Significant changes in biological function in QSI adapted EC958.

GO biological process complete	Number of genes	Change	P value	Fold enrichment	637
					638
Cinnamaldehyde					
Locomotion	25	-	1.01×10^{-6}	3.51	639
Chemotaxis	15	-	4.39×10^{-6}	5.19	
Toxin biosynthetic processes	7	+	1.76×10^{-4}	9	640
Reactive nitrogen species metabolic process	16	-	7.58×10^{-7}	5.76	
Bacterial flagellum dependent motility	14	-	1.81×10^{-4}	3.29	641
Drug catabolic processes	24	+	6.41×10^{-5}	2.77	
Response to stress	91	+	3.01×10^{-4}	1.49	642
F-DPD					
Locomotion	25	-	6.29×10^{-17}	10.86	643
Regulation of chemotaxis	4	-	8.8×10^{-5}	27.79	
Bacterial flagellum assembly	7	-	1.12×10^{-5}	11.44	644
Furanone-C30					
IMP biosynthetic process	7	+	9.61×10^{-6}	12.65	645
Sulfate transmembrane transport	4	+	4.19×10^{-4}	15.49	
Ribosomal large subunit assembly	13	-	6.72×10^{-10}	12.58	646
Ribosomal small subunit assembly	9	-	3.98×10^{-7}	12.20	
Translation	34	-	5.08×10^{-19}	7.81	647
Reactive nitrogen species metabolic process	7	+	1.01×10^{-4}	7.59	
Drug catabolic process	10	+	1.01×10^{-3}	3.47	648
Carbohydrate catabolic processes	14	+	8.45×10^{-4}	2.77	
-----	-----	-----	-----	-----	649
Control					
Reactive nitrogen species metabolic process	10	-	9.17×10^{-4}	3.92	650
Ribosome assembly	19	+	1.44×10^{-5}	3.58	
Aromatic amino acid family biosynthetic process	12	+	7.13×10^{-4}	3.46	651
Cellular biosynthetic processes	156	+	4.92×10^{-7}	1.32	
Cellular respiration	33	+	1.65×10^{-6}	2.79	652

653 Effects of long-term exposure to QSIs on the transcriptome, data shows differential gene expression in the QSI exposed isolates (P12) compared
654 to the respective passaged controls (C12) (controlling for repeated passaging). Control data shows changes in biological function after repeated
655 passage by comparing the unexposed isolate (P0) to the control passaged isolate (C12). RNA-sequencing was performed using three biological
656 repeats.

657